NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
06/10/2024
Back to search
Official data from USPTO
CYPRIUM THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CYPRIUM THERAPEUTICS
ST13
US500000087978937Class
42
Filing
87978937
Registration
5624302
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
06/10/2024
Trademark type
Word
Nice classes
42
Filing date
03/15/2017
Registration date
12/04/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/10/2024
Last transaction
06/10/2024
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2017-03-00
First use in commerce
2017-03-00
Drawing code
4
Owner type
03
Owner location
New York, NY
Examiner
JOHNSON, DONALD
Current location
FILE DESTROYED
Holders and representatives
Holders
Cyprium Therapeutics, Inc.
Representatives
Devon E. White WYRICK ROBBINS YATES & PONTON LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Development of pharmaceutical preparations and medicines; Development of pharmaceutical preparations and medicines for the treatment of Menkes disease and copper transport and metabolism diseases and disorders; Development of pharmaceutical preparations and medicines for the treatment of diseases and disorders where copper deficiency is present; Development of pharmaceutical preparations and medicines for the treatment of hematological and neurological disorders; Laboratory research services relating to pharmaceuticals; Medical research services; Pharmaceutical drug development services; Scientific research for medical purposes in the field of Menkes disease and copper transport and metabolism diseases and disorders; Scientific research for medical purposes in the field of diseases and disorders where copper deficiency is present; Scientific research for medical purposes in the field of hematological and neurological disorders ; Research in the field of pharmacogenetics; Conducting clinical trials for others in the field of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
35 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
06/10/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/10/2024
E815
TEAS SECTION 8 & 15 RECEIVED
12/04/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/04/2018
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/31/2018
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/30/2018
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/25/2018
DPCC
DIVISIONAL PROCESSING COMPLETE
10/25/2018
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/26/2018
IUAF
USE AMENDMENT FILED
09/24/2018
DRRR
DIVISIONAL REQUEST RECEIVED
09/24/2018
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
09/24/2018
EISU
TEAS STATEMENT OF USE RECEIVED
09/24/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/10/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/13/2018
PUBO
PUBLISHED FOR OPPOSITION
02/13/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/24/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/03/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/03/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/02/2018
GNRT
NON-FINAL ACTION E-MAILED
01/02/2018
CNRT
NON-FINAL ACTION WRITTEN
01/02/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/14/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/13/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/13/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/13/2017
GNRT
NON-FINAL ACTION E-MAILED
06/13/2017
CNRT
NON-FINAL ACTION WRITTEN
06/13/2017
DOCK
ASSIGNED TO EXAMINER
06/08/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/21/2017
NWAP
NEW APPLICATION ENTERED
03/18/2017
Continuous trademark protection
Get notified about every new filing that threatens CYPRIUM THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.